Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
RESEARCH TOOLSreports
MRSN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.49 - $6.28
Previous CloseN/A
Volume429.52K
Average Volume (3M)8.22M
Market Cap
$71.99M
Enterprise Value$108.28M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.93
Next Earnings
Feb 26, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding123,532,906
10 Day Avg. Volume5,364,209
30 Day Avg. Volume8,224,458
Standard Deviation0.35
R-Squared0.04
Alpha-0.00370
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.06
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.97
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$4.67Price Target Upside733.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Mersana Therapeutics News
PremiumCompany Announcements
Mersana Therapeutics Updates Investor Presentation Online
PremiumCompany Announcements
Mersana Therapeutics Gains Fast Track for Emi-Le---
Bulls Say, Bears Say
Bulls Say
Competitive LandscapePfizer's decision to discontinue their B7-H4 program is seen as a positive for MRSN, as it removes a key competitor and allows Emi-Li to be an increasingly relevant therapy in the post Topo-I ADC treated TNBC market.
EfficacyEmi-Li continues to show the best response rate among post Topo-I ADC treated TNBC patients, which is an area with high unmet need.
Market OpportunityMersana's target and secondary indications offer a significant total addressable market opportunity.
Bears Say
Clinical RisksClinical and regulatory risks are the most material risks to the Outperform rating.
Comparative EfficacySkeptics may be tempted to cross-compare Emi-Le's data to that of PFE's felmetatug vedotin and highlight MRSN's numerically-lower cORR.
Response RatesThe objective response rate for B7-H4-high TNBC patients treated with intermediate dose levels falls short of the higher rates reported by competitors.
---
Ownership Overview
17.71% Insiders
8.98% Mutual Funds
51.23% Other Institutional Investors
11.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRSN FAQ
What was Mersana Therapeutics Inc’s price range in the past 12 months?
Mersana Therapeutics Inc lowest stock price was $0.49 and its highest was $6.28 in the past 12 months.
What is Mersana Therapeutics Inc’s market cap?
Mersana Therapeutics Inc’s market cap is $71.99M.
When is Mersana Therapeutics Inc’s upcoming earnings report date?
Mersana Therapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Mersana Therapeutics Inc’s earnings last quarter?
Mersana Therapeutics Inc released its earnings results on Nov 13, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.082.
Is Mersana Therapeutics Inc overvalued?
According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued.
Does Mersana Therapeutics Inc pay dividends?
Mersana Therapeutics Inc does not currently pay dividends.
What is Mersana Therapeutics Inc’s EPS estimate?
Mersana Therapeutics Inc’s EPS estimate is -0.16.
How many shares outstanding does Mersana Therapeutics Inc have?
Mersana Therapeutics Inc has 123,532,906 shares outstanding.
What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?
Mersana Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went up 19.545%.
Which hedge fund is a major shareholder of Mersana Therapeutics Inc?
Currently, no hedge funds are holding shares in MRSN
---
Mersana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (733.93% Upside)
$4.67 (733.93% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 75.3%
Last 30 Days ▲ 75.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.68%
12-Months-Change
Fundamentals
Return on Equity
-280.29%
Trailing 12-Months
Asset Growth
-35.52%
Trailing 12-Months
Company Description
Mersana Therapeutics Inc
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
---
MRSN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strong financial management, and successful collaborations, indicating a positive outlook. However, challenges remain in addressing resistance to TOPO1 ADCs and uncertainties in benchmarking efficacy.Read More>---
MRSN Stock 12 Month Forecast
Average Price Target
$4.67
▲(733.93% Upside)
Technical Analysis
Sarepta Therapeutics
―
MacroGenics
―
Karyopharm Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering MRSN
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-6.58%
upgraded a buy rating 12 months ago
Copying David Nierengarten's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -6.58% per trade.
---